Shop by goal

Popular compounds

GHK-Cu Copper Peptide

GLP1-RC-RT

Research resources

Survodutide (BI 456906): A Research Guide to the GLP-1 / Glucagon Dual Agonist

Short answer: survodutide (BI 456906) is a GLP-1 + glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma, given once weekly. The glucagon arm makes it as much a liver drug as a weight drug — it holds U.S. FDA Breakthrough Therapy status for the liver disease MASH, and the Phase 3 SYNCHRONIZE-1 obesity trial met both primary endpoints and cut liver fat by up to ~63%. It has no marketing authorisation anywhere as of mid-2026. New-U does not sell survodutide. Part of our next obesity-research wave overview.

Plain-English summary. Survodutide is an unapproved, investigational drug. Breakthrough Therapy designation speeds FDA review — it is not an approval. The FDA, MHRA and EMA have not authorised survodutide. This page is general information, not legal or medical advice; do not use unapproved compounds on people.

What survodutide actually is

Survodutide (developmental code BI 456906 ) is a synthetic peptide dual agonist of the GLP-1 and glucagon receptors, given as a once-weekly subcutaneous injection. It was discovered at Zealand Pharma and licensed to Boehringer Ingelheim, which leads its global development and commercialisation. Molecular and trial detail is indexed under PubMed: survodutide / BI 456906.

Why the glucagon arm is the story

Adding glucagon to GLP-1 changes what the drug does :

GLP-1 receptor — appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion (the familiar incretin effects).

Glucagon receptor — raises energy expenditure and, crucially, drives hepatic fat mobilisation . On its own glucagon would raise blood glucose; paired with GLP-1 that effect is offset, leaving the energy-expenditure and liver-fat arms.

This is the same dual logic behind the glucagon arm of retatrutide — except retatrutide adds GIP on top, whereas survodutide stays a focused GLP-1/glucagon pairing aimed squarely at weight and liver.

The MASH angle

Because the glucagon arm pulls fat out of the liver, survodutide is being developed for MASH (metabolic dysfunction-associated steatohepatitis — the serious, fibrosing form of fatty liver disease) as well as obesity. The U.S. FDA granted survodutide Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis in September 2024. Its liver programme runs under the LIVERAGE Phase 3 studies.

The trial evidence

Trial Indication Result SYNCHRONIZE-1 (Phase 3, 76 wks, n=725) Obesity, no diabetes Met both primary endpoints; liver fat reduced up to ~63.1% SYNCHRONIZE-MASLD (Phase 3) Fatty liver ~6 in 10 reached liver-fat normalisation at 48 wks Phase 2 obesity Obesity Mean weight reduction in the high teens (%) over ~46 wks Phase 2 MASH MASH / fibrosis Significant improvement in liver fibrosis vs placebo

The SYNCHRONIZE-1 obesity results were published in the New England Journal of Medicine . Topline weight-loss magnitude and full secondary endpoints should be read from the primary publication rather than summarised here as a single headline number, because trial design and estimands matter.

How survodutide compares

Compound Receptor profile Standout indication Status Survodutide GLP-1 + glucagon Obesity + MASH Phase 3, no approval Retatrutide GLP-1 + GIP + glucagon Obesity (incl. MASH arm) Phase 3, no approval Tirzepatide GLP-1 + GIP Obesity / type-2 diabetes Approved Semaglutide GLP-1 Obesity / cardiovascular Approved

Survodutide and research compounds

Survodutide is a proprietary Boehringer Ingelheim / Zealand molecule and is not catalogued by research-compound suppliers. New-U does not sell survodutide. The closest established research reference that also carries a glucagon arm is the triple agonist:

Retatrutide — the GLP-1 / GIP / glucagon triple-agonist reference peptide.

Semaglutide and tirzepatide for the GLP-1 and GLP-1/GIP baselines.

Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity, with the per-batch Certificate of Analysis published online — research use only .

Frequently Asked Questions

What is survodutide? A GLP-1 + glucagon dual agonist (BI 456906) from Boehringer Ingelheim and Zealand Pharma, dosed once weekly, developed for obesity and MASH.

Is survodutide approved? No. As of mid-2026 it has no marketing authorisation; it is in Phase 3. Its MASH Breakthrough Therapy status speeds review but is not approval.

How is it different from semaglutide? It adds glucagon-receptor agonism, which raises energy expenditure and mobilises liver fat — a weight-and-liver drug.

What did the trials show? SYNCHRONIZE-1 (Phase 3 obesity) met both primary endpoints and cut liver fat up to ~63%; Phase 2 MASH data showed fibrosis improvement.

Can I buy survodutide for research? No — it is proprietary. New-U catalogues the glucagon-arm reference retatrutide instead. Research use only.

Primary sources & further reading

Boehringer Ingelheim — SYNCHRONIZE-1 Phase 3 obesity results

Boehringer Ingelheim — Survodutide MASH Breakthrough Therapy & Phase 3

U.S. National Library of Medicine — PubMed: survodutide / BI 456906

ClinicalTrials.gov — SYNCHRONIZE & LIVERAGE programmes

U.S. FDA — FDA (no survodutide approval as of publication)

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Glucagon-Arm Research Reference

New-U Research Compounds catalogues retatrutide — the triple agonist whose glucagon arm parallels survodutide’s — plus semaglutide and tirzepatide, as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with the per-batch Certificate of Analysis published online. Research use only - all claims made on this site are for testing and research use only.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research